Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...

Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, while ...

Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...